Rick Yang

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Menlo Park, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Zachary Bambach, attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Rick Yang

Form 4 holding 10%+ Owner

Savara Inc

Security class
Common Stock
Shares / value
24,471,264
Estimated value
$108,897,125
Report date
17 Jul 2023
Price
$4.45
Ownership
Indirect
Form 4 holding 10%+ Owner

MBX Biosciences, Inc.

Security class
Common Stock
Shares / value
3,614,486
Estimated value
$38,638,855
Report date
16 Sep 2024
Price
$10.69
Ownership
Indirect
Form 4 holding 10%+ Owner

Korro Bio, Inc.

Security class
Pre-Funded Warrants
Shares / value
242,945
Estimated value
Report date
10 Mar 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

MBX Biosciences, Inc.

Security class
Series A Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
16 Sep 2024
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

MBX Biosciences, Inc.

Security class
Series B Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
16 Sep 2024
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Monte Rosa Therapeutics, Inc.

Security class
Series A-2 convertible preferred stock
Shares / value
0
Estimated value
Report date
28 Jun 2021
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Monte Rosa Therapeutics, Inc.

Security class
Series B convertible preferred stock
Shares / value
0
Estimated value
Report date
28 Jun 2021
Price
$2.00
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Monte Rosa Therapeutics, Inc.

Security class
Series C convertible preferred Stock
Shares / value
0
Estimated value
Report date
28 Jun 2021
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

NeueHealth, Inc.

Security class
Series A Convertible Perpetual Preferred Stock
Shares / value
0
Estimated value
Report date
02 Oct 2025
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

NeueHealth, Inc.

Security class
Series B Convertible Perpetual Preferred Stock
Shares / value
0
Estimated value
Report date
02 Oct 2025
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

NeueHealth, Inc.

Security class
Warrant (Right to Buy)
Shares / value
0
Estimated value
Report date
02 Oct 2025
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

SpyGlass Pharma, Inc.

Security class
Series C-1 Preferred Stock
Shares / value
0
Estimated value
Report date
09 Feb 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

SpyGlass Pharma, Inc.

Security class
Series C-2 Preferred Stock
Shares / value
0
Estimated value
Report date
09 Feb 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Rick Yang

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .